Histotype
Mammary/Breast
| Parameter | Information |
|---|---|
| Strain | NSG |
| Implant Type | Cells |
| Implant Location | SC, Axilla |
| Time to Staging | 7 days |
| Time to Evaluation Size 750mm³ | 35 days |
| Td | 14.8 days |
The above parameters are from one study. For further information on this cell line and other parameters, including different strains, vendors, implant type and location and/or standards of care, please contact us.
Tumor Line
Human
Ref #
3846
Spotlight on BT-474 Human ductal breast carcinoma
Learn more about this cell line in our scientific spotlights:
The BT-474 cell line has a long history, but many of us thought it had run its natural course and was quickly becoming obsolete. The American Type Culture Collection (ATCC) reports that the BT-474 cell line was originally established in 1978 by E. Y. Lasfargues, who obtained a tumor biopsy from a 60-year-old woman with advanced stage invasive ductal breast carcinoma. The cell line was later classified as estrogen receptor positive (ER), progesterone receptor positive (PR) and human epidermal growth factor receptor 2 positive (HER2) (1). This information was critical in linking the BT-474 model used in preclinical breast cancer research to real patients with the same genetic profile.